Narrative Building for the Future of LPBI Group: List of Talking Points
Exchange between Gail and Aviva
On Tuesday, June 25, 2019, 11:43:27 AM EDT, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
HOW can we get Kevin Landwher of terarecon.com to create a Podcast for LPBI Group IP Assets, including a section on our forthcoming Genomics, Volume 2
In response to this question we are in discussion on POINTS #1,2,3,4
From: Gail Thornton <gailsthornton@yahoo.com>
Reply-To: Gail Thornton <gailsthornton@yahoo.com>
Date: Sunday, June 30, 2019 at 8:38 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, Rick Mandahl <rmandahl@gmail.com>, Amnon Danzig <amnon.danzig@gmail.com>
Subject: Please AUDIT PODCAST —>>>>>>>> Beyond the Screen Episode 6: Next Generation AI Companies Providing Physicians a Starting Point in AI
Aviva:
These videos from terarecon.com typically focus on one topic (not many as you’ve described below).
If there are too many topics proposed to this company, they will not be interested.
My recommendation is for you to finalize Genomics, volume 2, and let’s see the story we have about that specific topic.
Gali
On Tuesday, June 25, 2019, 11:43:27 AM EDT, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
HOW can we get Kevin Landwher of terarecon.com to create a Podcast for LPBI Group IP Assets, including a section on our forthcoming Genomics, Volume 2
On Saturday, June 29, 2019, 03:56:08 PM EDT, Aviva Lev-Ari <aviva.lev-ari@comcast.net> wrote:
POINT #1 for VIDEO coverage – Focus on Genomics, Volume 2
After 7/15, Prof. Feldman will be back in the US, stating to work on Part 5 in Genomics, Volume 2. We will Skype to discuss what to include in 5.1, 5.2, 5.3, 5.4
On 7/15, I am submitting my work on creation of Parts 1,2,3,4,6
Dr. Williams and Dr. Saha are working already on Part 7&8.
Below you have abbreviated eTOCs.
Go to URL of the Book to see what I placed already inside this book.
Dr. Williams and Prof. Feldman will compose
Preface
Introduction to Volume 2
Volume Summary
Epilogue
Based on these four parts and the eTOCs you will have ample content for the video, which may start with the epitome of our book creation: Genomics Volume 2 (you interview the three Editors why it is Epitome)
POINT #2 or #3 or #4 for VIDEOs to Focus on coverage for Marketing LPBI Group
by DESCRIPTION of what was accomplished
- Venture history/background
- Venture milestones: all posts in the Journal with the Title
- “We celebrate …..
- 5-6 Titles like that, I may add two more
- Site Statistics
- Book articles cumulative views (Article Scoring System: Data Extract)
- section on BioMed e-Series
- section on List of Conference covered in Real Time
- FIT Team input to Venture Valuation: top 5 or top 10 Factors in consensus
- the 3D graphs on Opportunity Maps: Gail, Rick, Amnon, Aviva – each explains their own outcome
- section on Pipeline
Video on What is the Ideal Solution for the FUTURE of LPBI Group
- Interviews with All FIT Members
For POINT #1:
To build the narrative for a VIDEO dedication to Genomics, Volume Two and Marketing campaign as a NEW BOOK on NGS, the Narrative will use content extracts to built a CASE for
Why GENOMICS Volume 2 – is the Epitome of all BioMed e-Series???????
forthcoming Genomics, Volume 2
Aviva completed Parts 1,2,3,4,6,
[5 is by Prof. Feldman]
[7,8 are by Scientists on FIT]:
Latest in Genomics Methodologies for Therapeutics:
Gene Editing, NGS & BioInformatics,
Simulations and the Genome Ontology
2019
Volume Two
Prof. Marcus W. Feldman, PhD, Editor
Prof. Stephen J. Williams, PhD, Editor
And
Aviva Lev-Ari, PhD, RN, Editor
Abbreviated eTOCs
Part 1: NGS
1.1 The Science
1.2 Technologies and Methodologies
1.3 Clinical Aspects
1.4 Business and Legal
Part 2: CRISPR for Gene Editing and DNA Repair
2.1 The Science
2.2 Technologies and Methodologies
2.3 Clinical Aspects
2.4 Business and Legal
Part 3: AI in Medicine
3.1 The Science
3.2 Technologies and Methodologies
3.3 Clinical Aspects
3.4 Business and Legal
3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset
Part 4: Single Cell Genomics
4.1 The Science
4.2 Technologies and Methodologies
4.3 Clinical Aspects
4.4 Business and Legal
Part 5: Evolution Biology Genomics Modeling @Feldman Lab, Stanford University – Written and Curated by Prof. Marc Feldman
5.1
5.2
5.3
5.4
Part 6: Simulation Modeling in Genomics
6.1 Mutation Analysis – Gene Encoding
6.2 Mitochondrial Variations
6.3 Variant Analysis
6.4 Variant Detection in Hereditary Cancer Genes
6.5 Immuno-Informatics
6.6 RNA Sequencing
6.7 Complex Insertions and Deletions
6.8 Evolutionary Biology
6.9 Simulation Programs
6.10 A comparison of tools for the simulation of genomic next-generation sequencing data
Part 7: Applications of Genomics: Genotypes, Phenotypes and Complex Diseases
7.1 Genome-wide associations with complex diseases (GWAS)
7.2 Non-coding DNA and phenotypes—including diseases like cancer
7.3 Epigenomic associations with phenotypes including cancer
7.4 Rare variants and diseases
7.5 Population-level genomics and the meaning of group differences
7.6 Targeting drugs for complex diseases
Part 8: Epigenomics and Genomic Regulation
8.1 Genomic controls on epigenomics
8.2 The ENCODE project and gene regulation
8.3 Small interfering RNAs and gene expression
8.4 Epigenomics in cancer
8.5 Environmental epigenomics
Leave a Reply